Millions of euros of candidiasis for epilepsy will be developed in Latvia – in Latvia – News

"This story is about the fact that we already have a well-described main link, but there is still a long way to go, but this path is currently well marked and, above all, it enjoys financial support "said Pugovich.

He pointed out that in the beginning he was working on a memory stimulator, but the purpose of the research changed in a treatment for epilepsy, because the results were positive and effective in the treatment of epilepsy. According to him, the new substance has no psychotropic effect, but there is a postulated mechanism of action that suggests that epilepsy could be the most promising diagnosis for its use.

Pugovich said that after the research process, the Latvian Institute of Organic Synthesis reached the stage Think about how to develop this substance. Initially, the Institute has held discussions with pharmaceutical companies, but they showed that the idea was not yet mature enough. Therefore, the Institute has submitted a project to the European Union Investment and Development Agency for the financing of the Structural Funds of the European Union in the Program of the European Union. Technology Transfer, getting 300,000 euros for the development and marketing of a drug candidate. For years, we would have a chemical compound in our hands, which would be called a drug candidate, and if any of these drugs is purchased, the next phase will be the first phase of the clinical trial in which the safety of the new substance will be achieved. This distance to the final product is the three years already mentioned, during which we must do our homework in the sector, in the development of manufacturing technology, in the technological scale, and there could be at least four years when all clinical research is done. It's time for the final product, then, it's time for the final product, "stressed Pugovich

He noted that the Latvian Institute of Organic Synthesis has not been active in systematic development new drugs since the 80s of the last century.A drug for cardiovascular disease – Meldonium, commonly known as Mildronate.Other drugs, including a cancer drug belinostat, were created by the 39 Institute in cooperation with other scientific institutions and commercial structures when the EU structural funds were not yet available for research. "We have never been those who determine themselves what to do and how to work, which is fascinating and gives us a lot of challenges, "said the director of the institute.

He noted that funding from the Structural Funds European was attracted, Indeed, at an early stage of the project, it is difficult for a project to attract private investors. Pugovich said that they usually want to invest money in projects where returns can be seen in the short term. In addition, the Latvian Institute of Organic Synthesis has not gained scientific reputation for several hundred years, as is the case of the Oxford, Cambridge Universities and Harvard, for which wealthy patrons finance the development of scientific ideas. "In our case, the alternative is really the Structural Funds. (..) It takes three years and I think we will already have a product that can be put on sale as a showcase for the next developer", declared Pugovich. [ad_2]
Source link